Can-Fite BioPharma Ltd. (CANF): R&D Expense
$6.69M
Year ended 2025-12-31
-4.8%
3-year compound annual growth
-10.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.69M | +16.3% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $5.76M | -3.8% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $5.98M | -22.9% | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | $7.76M | -21.2% | 2025-04-14, From 2022-01-01 |
| 2021-12-31 | $9.85M | -17.6% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $11.95M | +8.9% | 2023-03-30, From 2020-01-01 |
| 2019-12-31 | $10.98M | +80.7% | 2022-03-24, From 2019-01-01 |
| 2018-12-31 | $6.08M | +19.0% | 2021-03-25, From 2018-01-01 |
| 2017-12-31 | $5.11M | -16.5% | 2020-03-27, From 2017-01-01 |
| 2016-12-31 | $6.12M | n/a | 2019-03-29, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
Compare CANF, MNOV, SCNX, PVCT side by side · Screen every company in Pharmaceutical Preparations ↗